After the successful trial of Covaccine, the hopes of safely opening primary and secondary schools in the country have also increased.
The way has been cleared for applying Covaxin to children in the age group of two years to 18 years in the country to control COVID-19 infection. Vaccine maker Bharat Biotech has said that the trial of covaccine on children between two and 18 years has been successful. After the successful trial of Covaccine, the hopes of safely opening primary and secondary schools in the country have also increased. Covaccine had already got emergency use permission for 12 to 18 years. After this, the government has announced to vaccinate children in the age group of 15 to 18 years from January 3.
Study finds vaccine safe for children – Bharat Biotech
Krishna Ella, CMD, Bharat Biotech, said, “The clinical data on covaccine in children is very encouraging. Vaccine safety is important for children. We are pleased to report that Covaccine now has proven data for safety and immunity in children. We have now achieved our goal of developing a safe and effective COVID-19 vaccine for adults and children.” Bharat Biotech conducted a Phase II and III, open-label and multi-study to determine the safety, reactogenicity and immunogenicity of Covaxin in healthy children and adolescents aged 2 to 18 years.
Covid 19 Vaccination: Precaution dose of corona vaccine will be imposed in the country from January 10, see here the complete details of the guidelines related to it
‘Not aware of any serious reaction’
The company said in its statement that in the study, no serious reaction was reported. A total of 374 volunteers reported symptoms of either mild or moderate severity, with 78.6 per cent recovering within a day. However, complaints of pain are being received at the injection site.
Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.
.